Regeneron Pharmaceuticals (REGN) Competitors $546.51 +1.05 (+0.19%) As of 02:40 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock REGN vs. AMGN, GILD, MRNA, NTLA, VIR, VRTX, ABBV, LLY, MRK, and PFEShould you be buying Regeneron Pharmaceuticals stock or one of its competitors? The main competitors of Regeneron Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Moderna (MRNA), Intellia Therapeutics (NTLA), Vir Biotechnology (VIR), Vertex Pharmaceuticals (VRTX), AbbVie (ABBV), Eli Lilly and Company (LLY), Merck & Co., Inc. (MRK), and Pfizer (PFE). These companies are all part of the "medical" sector. Regeneron Pharmaceuticals vs. Its Competitors Amgen Gilead Sciences Moderna Intellia Therapeutics Vir Biotechnology Vertex Pharmaceuticals AbbVie Eli Lilly and Company Merck & Co., Inc. Pfizer Regeneron Pharmaceuticals (NASDAQ:REGN) and Amgen (NASDAQ:AMGN) are both large-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, risk, institutional ownership and dividends. Is REGN or AMGN a better dividend stock? Regeneron Pharmaceuticals pays an annual dividend of $3.52 per share and has a dividend yield of 0.6%. Amgen pays an annual dividend of $9.52 per share and has a dividend yield of 3.2%. Regeneron Pharmaceuticals pays out 9.0% of its earnings in the form of a dividend. Amgen pays out 86.9% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Amgen has increased its dividend for 14 consecutive years. Amgen is clearly the better dividend stock, given its higher yield and longer track record of dividend growth. Does the media refer more to REGN or AMGN? In the previous week, Regeneron Pharmaceuticals had 2 more articles in the media than Amgen. MarketBeat recorded 47 mentions for Regeneron Pharmaceuticals and 45 mentions for Amgen. Amgen's average media sentiment score of 1.35 beat Regeneron Pharmaceuticals' score of 1.06 indicating that Amgen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Regeneron Pharmaceuticals 26 Very Positive mention(s) 4 Positive mention(s) 11 Neutral mention(s) 5 Negative mention(s) 0 Very Negative mention(s) Positive Amgen 40 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders believe in REGN or AMGN? 83.3% of Regeneron Pharmaceuticals shares are owned by institutional investors. Comparatively, 76.5% of Amgen shares are owned by institutional investors. 7.0% of Regeneron Pharmaceuticals shares are owned by company insiders. Comparatively, 0.8% of Amgen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Which has preferable earnings & valuation, REGN or AMGN? Regeneron Pharmaceuticals has higher earnings, but lower revenue than Amgen. Regeneron Pharmaceuticals is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRegeneron Pharmaceuticals$14.20B4.15$4.41B$39.2813.91Amgen$33.42B4.79$4.09B$10.9627.14 Which has more volatility & risk, REGN or AMGN? Regeneron Pharmaceuticals has a beta of 0.33, suggesting that its stock price is 67% less volatile than the S&P 500. Comparatively, Amgen has a beta of 0.49, suggesting that its stock price is 51% less volatile than the S&P 500. Do analysts rate REGN or AMGN? Regeneron Pharmaceuticals presently has a consensus price target of $828.86, suggesting a potential upside of 51.66%. Amgen has a consensus price target of $307.27, suggesting a potential upside of 3.30%. Given Regeneron Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe Regeneron Pharmaceuticals is more favorable than Amgen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Regeneron Pharmaceuticals 1 Sell rating(s) 6 Hold rating(s) 15 Buy rating(s) 2 Strong Buy rating(s) 2.75Amgen 2 Sell rating(s) 12 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.35 Is REGN or AMGN more profitable? Regeneron Pharmaceuticals has a net margin of 31.94% compared to Amgen's net margin of 17.39%. Amgen's return on equity of 176.11% beat Regeneron Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Regeneron Pharmaceuticals31.94% 15.27% 11.93% Amgen 17.39%176.11%12.39% SummaryRegeneron Pharmaceuticals beats Amgen on 11 of the 20 factors compared between the two stocks. Get Regeneron Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for REGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding REGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart REGN vs. The Competition Export to ExcelMetricRegeneron PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$58.99B$2.98B$5.45B$9.29BDividend Yield0.63%2.39%4.71%4.06%P/E Ratio13.9123.3429.4724.30Price / Sales4.15282.80418.80168.61Price / Cash12.1442.2235.8358.21Price / Book2.048.488.275.54Net Income$4.41B-$55.06M$3.24B$259.03M7 Day Performance-2.95%-4.27%-3.77%-4.63%1 Month Performance2.17%12.19%5.61%5.86%1 Year Performance-50.01%3.50%22.78%15.16% Regeneron Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)REGNRegeneron Pharmaceuticals4.8209 of 5 stars$546.51+0.2%$828.86+51.7%-49.5%$58.99B$14.20B13.9115,106Trending NewsAnalyst ForecastGap UpAMGNAmgen4.5353 of 5 stars$301.54-0.7%$307.27+1.9%-11.2%$162.18B$33.42B27.5228,000Positive NewsUpcoming EarningsGILDGilead Sciences4.8363 of 5 stars$115.11+0.8%$112.36-2.4%+47.6%$143.33B$28.75B24.2617,600Positive NewsUpcoming EarningsInsider TradeMRNAModerna4.4527 of 5 stars$32.62-0.1%$46.11+41.4%-75.2%$12.60B$3.24B-3.735,800Trending NewsEarnings ReportAnalyst ForecastOptions VolumeGap DownNTLAIntellia Therapeutics4.4073 of 5 stars$12.71+1.6%$33.37+162.6%-55.6%$1.32B$57.88M-2.43600News CoverageUpcoming EarningsGap DownVIRVir Biotechnology3.4838 of 5 stars$5.37+2.2%$30.25+463.8%-50.1%$743.04M$74.21M-1.27580News CoverageUpcoming EarningsShort Interest ↑VRTXVertex Pharmaceuticals4.3018 of 5 stars$470.75+0.5%$512.30+8.8%-7.8%$120.98B$11.02B-120.186,100Positive NewsUpcoming EarningsShort Interest ↑ABBVAbbVie4.5912 of 5 stars$190.84-0.2%$211.29+10.7%+2.0%$337.65B$56.33B81.3455,000Trending NewsEarnings ReportAnalyst ForecastLLYEli Lilly and Company4.9204 of 5 stars$768.04+0.7%$1,012.56+31.8%-8.0%$725.79B$49.00B62.3147,000Trending NewsUpcoming EarningsMRKMerck & Co., Inc.4.9963 of 5 stars$82.610.0%$107.44+30.1%-30.9%$207.59B$64.17B12.0375,000Positive NewsEarnings ReportAnalyst ForecastOptions VolumeAnalyst RevisionPFEPfizer4.9546 of 5 stars$24.09-0.9%$28.55+18.5%-23.8%$137.05B$63.63B17.4781,000Trending NewsUpcoming Earnings Related Companies and Tools Related Companies Amgen Alternatives Gilead Sciences Alternatives Moderna Alternatives Intellia Therapeutics Alternatives Vir Biotechnology Alternatives Vertex Pharmaceuticals Alternatives AbbVie Alternatives Eli Lilly and Company Alternatives Merck & Co., Inc. Alternatives Pfizer Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:REGN) was last updated on 8/1/2025 by MarketBeat.com Staff From Our PartnersWall Street Hates This Gold IRA Strategy—Here’s WhyWhat if I told you there's a legal way to own real physical gold and silver—and keep your gains tax-free? N...Advantage Gold | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredI’d rather trade news like this than gamble on hypeReal traders are watching Nvidia’s next move—after U.S. approval to resume chip sales to China. This reversal ...Timothy Sykes | SponsoredThis New Rule Could Change EverythingA major change is quietly going into effect this July — and Wall Street is already positioning for it. Big ...American Alternative | SponsoredBREAKING: The House just passed 3 pro-crypto bills!99.8% voted YES on this crypto partnership Kraken—one of the world's biggest crypto exchanges—just picked O...Crypto 101 Media | SponsoredIf you saw this, you'd be scared tooMarkets may look strong—but one veteran analyst warns we’re nearing a financial breaking point. After 40+ y...InvestorPlace | SponsoredWhy “The Prophet” Is Betting Big on This $10 StockAmerica's Biggest Land Grab Is Not Where You Think While the media focuses on coastal cities and farmland.....Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Regeneron Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Regeneron Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
